Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The clinical benefits of sunitinib and sorafenib have been demonstrated in patients with
cytokine-refractory metastatic renal cell carcinoma. Sunitinib has also been shown to improve
progression free survival and overall survival in a comparative study with interferon-alpha.
When sunitinib is used as first-line molecular-targeted therapy, switching to sorafenib is
one of the treatment options after disease progression. Reversely, when sorafenib is used as
first-line molecular-targeted therapy, sunitinib is used as second-line therapy. The goal of
cancer treatment is cure, and if cure is not possible, it is to prolong survival. In this
study, sunitinib or sorafenib will be administered as first-line molecular-targeted therapy
and treatment switched to the other test drug, sorafenib or sunitinib, when disease
progression is detected to assess which treatment sequence produces longer progression free
survival and offers a better safety profile (causing fewer adverse events). The purpose of
this trial is to compare progression free survival of first line sunitinib versus sorafenib,
and that of two treatment sequences, i.e. sunitinib followed by sorafenib versus sorafenib
followed by sunitinib.